Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease

Annals of Pharmacotherapy

Volumn 42, Issue 12, 2008, Pages 1832-1842

  Chen, Andrea M ^a   Bollmeier, Suzanne G ^a   Finnegan, Patrick M ^a  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

Combination therapy; COPD; Formoterol; Long acting 2 agonists; Long acting anticholinergics; Pharmacoeconomics; Safety; Salmeterol; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALMETEROL; TIOTROPIUM BROMIDE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOKALEMIA; MEDLINE; MONOTHERAPY; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPIROMETRY; TACHYCARDIA; TREMOR; WORLD HEALTH ORGANIZATION;

ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; ECONOMICS, PHARMACEUTICAL; HUMANS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 57449109515     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L250     Document Type: Review

References (67)

1. Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. www.goldcopd.org (accessed 2008 Mar 28).
2. Mannino DM, Homa DM, Akinbami LJ, Redd SC, Ford ES. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respir Care 2002;47:1148-9.
3. National Heart, Lung, and Blood Institute. Morbidity & mortality: 2007 chart book on cardiovascular, lung, and blood diseases. Bethesda MD: National Institutes of Health. www.nhlbi.nih.gov/resources/docs/07-chtbk.pdf (accessed 2008 Mar 14).
4. Prosser TR, Bollmeier SG. Chronic obstructive pulmonary disease. In: Dunsworth T, Richardson M, Chant C, et al., eds. Pharmacotherapy self-assessment program. 6th ed. Pulmonary and critical care medicine. Lenexa, KS: American College of Clinical Pharmacy, April 2008:1-20.
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442. DOI 10.1371/journal.pmed. 0030442
6. World Health Organization. Mortality country fact sheet 2006. www.who.int/whosis/mort/profiles/mort_amro_usa_unitedstatesofamerica.pdf (accessed 2008 Mar 7).
7. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-9.
8. Redelmeier DA, Goldstein RS, Min ST, Hyland RH. Spirometry and dyspnea in patients with COPD. When small differences mean little. Chest 1996;109:1163-8. DOI 10.1378/chest.109.5.1163
9. Van Noord JA, Bantje TA, Eland ME, Korducki PJ, Cornelissen PJG. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55:289-94.
10. Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007;52:833-51.
11. Product information. Spiriva HandiHaler (tiotropium bromide inhalation powder). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., December 2006.
12. Olin JL. Tiotropium: an inhaled anticholinergic for chronic obstructive pulmonary disease. Am J Health-Syst Pharm 2005;62:1263-9.
13. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117(suppl):63-6. DOI 10.1378/chest.117.2_suppl.63S
14. Pappano AJ. Cholinoreceptor-blocking drugs. In: Katzung BG, ed. Basic and clinical pharmacology. 10th ed. New York: Lange Medical Books/McGraw-Hill, 2007. http://online.statref.com/document.aspx?fxid=2&docid=80 (accessed 2008 Mar 11).
15. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24. DOI 10.1183/09031936.02.00269802
16. Decramer M. Tiotropium as essential maintenance therapy in COPD. Eur Respir Rev 2006;15:51-7. DOI 10.1183/09059180.00009906
17. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-26.
18. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-62. DOI 10.1136/thx.2006.063271
19. Vincken W, Van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16. DOI 10.1183/09031936.02.00238702
20. Hoffman B. Adrenoceptor-activating and other sympathomimetic drugs. In: Katzung BG, ed. Basic and clinical pharmacology. 10th ed. New York: Lange Medical Books/McGraw-Hill, 2007. http://online.statref.com/documentaspx?fxid= 2&docid=90 (accessed 2008 Mar 11).
21. Product information. Serevent Diskus (salmeterol xinafoate inhalation powder). Research Triangle Park, NC: GlaxoSmithKline, March 2008.
22. Product information. Foradil Aerolizer (formoterol fumarate inhalation powder). Kenilworth, NJ: Schering Corporation, June 2006.
23. US Food and Drug Administration. Serevent label and approval history. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Label_ApprovalHistory#apphist (accessed 2008 Mar 14).
24. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994;7:103-7.
25. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995;89:357-62.
26. Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999;66:434-9.
27. 1 reversibility. Curr Med Res Opin 2004; 20:581-6. DOI 10.1185/030079904125003368
28. Kottakis J, Cioppa GD, Creemers J, et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002;9:107-15.
29. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003;21:86-94. DOI 10.1183/09031936.03.00020102
30. 2- agonists. Pharmacotherapy 2006;26(9 pt 2):164S-74S.
31. Rau JL. Inhaled adrenergic bronchodilators: historical development and clinical application. Respir Care 2000;45:854-63.
32. 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr Opin Pharmacol 2003;3:270-6.
33. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. Br Med J 1968;1:335-9.
34. Speizer FE, Doll R, Heaf P, Strang LB. Investigation into use of drugs preceding death from asthma. Br Med J 1968;1:339-43.
35. Tsagaraki V, Amfilochiou A, Markantonis SL. Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract 2006;60:415-21. DOI 10.1111/j.1368-5031.2006.00849
36. Dahl R, Greefhorst APM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84.
37. Van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Resp J 2005;26:214-22.
38. Cazzola M, Centanni S, Santus P, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004;98:1214-21. DOI 10.1016/j.rmed.2004.05.003
39. Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004;17:35-9. DOI 10.1016/j.pupt.2003.09.001
40. Donohue JF, Van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
41. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404.
42. Briggs DD, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005;18:397-404. DOI 10.1016/j.pupt.2005.02.013
43. Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am J Med 2006;119(10 suppl 1):S46-53.
44. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther 2007;20:495-502.
45. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994;105:1411-9. DOI 10.1378/chest.105.5.1411
46. Combivent Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514-21. DOI 10.1378/chest.112.6.1514
47. Campbell S. For COPD, a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999;159:156-60.
48. Van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509-17.
49. Van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878-85.
50. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium; a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119:1347-56.
51. Baloira Villar A, Vilarino Pombo C. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2005;41:130-4.
52. Nichols J. Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease. Pharmacotherapy 2007;27:447-54.
53. Jarvis S, Ind P, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing 2007;36:213-8.
54. Cramer JA, Bradley-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J 2007;14:25-9.
55. Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raajimakers JA, Herings RM. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 200;98:752-9.
56. Jara M, Lanes SF, Wentworth C III, May C, Kesten S. Comparative safety of long-acting inhaled bronchodilators. A cohort study using the UK THIN primary care database. Drug Safety 2007;30:1151-60.
57. Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo-and-active- controlled trial. Clin Ther 2007;29:2167-78.
58. Campbell SC, Criner GJ, Levine BE, et al. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2007;20:571-9.
59. US Food and Drug Administration. Early communication about an on-going safety review of tiotropium (marketed as Spiriva HandiHaler). www.fda.gov/cder/drug/early_comm/tiotropium.htm (accessed 2008 Oct 16).
60. Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc 2007;82:575-82.
61. Friedman M, Menjoge SS, Anton SF, Keston S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004;22:741-9.
62. Maniadakis N, Tzanakis N, Fragoulakis V, Hatzikou M, Saifakas N. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006;22:1599-607.
63. Rutten-Van Molken MPMH, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007;8:123-35.
64. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004;1:303-12.
65. 2-adrenoceptor agonists justified for chronic obstructive pulmonary disease? Drugs Aging 2007;24:615-28.
66. Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2005;2:272-81. DOI 10.1513/pats.200505-047SR
67. 2-agonist, in patients with COPD: a 28-day randomized, placebo controlled clinical trial. Pulm Pharm Ther 2007;20:740-9. Epub 2006 Sep 30.